Abstract:Considering recent findings that cyclooxygensase-2 (COX-2) is involved in the progression of colorectal carcinoma (CRC), the role of COX-2 in promoting invasion and angiogenesis was investigated by evaluating the relationship of COX-2 expression to various clinicopathological variables, including plasminogen activating system (PA system) and vascular endothelial growth factor (VEGF). Tumor tissues from 71 patients with CRC were assayed to determine the antigen levels of urokinase-type plasminogen activator (uP… Show more
“…In agreement with other studies, p53 overexpression was found in 50.3% (81/161) of the colorectal cancers. Many other studies have demonstrated that p53 overexpression in colorectal cancer was closely related to clinicopathologic parameters and prognosis 12,19. In our study, p53 overexpression was correlated with age and depth of tumor invasion.…”
Section: Discussionsupporting
confidence: 75%
“…In our study, the expression rate of COX-2 was found to be 47.8% by immunohistochemical analysis, a result slightly lower than that found in other studies. However, other studies have reported that overexpression of COX-2 protein has been found in 21% to 25% of colorectal cancers 12-14. The discrepancies in the positive rate of COX-2 protein expression among the different studies may be explained by several factors, including variability in population size and characteristics, antibodies, lack of standardization in testing methods, and especially the differences in the choice of the scoring system or cutoff levels.…”
PurposeCyclooxygenase (COX)-2 is an inducible isoform responsive to cytokines, mitogens, and growth factors, and is believed to be an important enzyme related to colorectal cancer (CRC). Existing evidence suggests that COX-2 expression is normally suppressed by wild-type p53 but not mutant p53, suggesting that loss of p53 function may result in the induction of COX-2 expression. The aim of this study was to determine the relationship between COX-2 expression and p53 levels in CRC.Materials and MethodsPatients with sporadic colorectal adenocarcinoma (n = 161) who underwent curative surgery in Chosun University Hospital were enrolled in this study. Expression of COX-2 and p53 proteins was examined by immunohistochemistry in paraffin-embedded cancer tissue blocks, and the relationship between COX-2 and/or p53 expression with clinicopathologic parameters was analyzed.ResultsExpression of COX-2 was positive in 47.8% of colorectal cancers, and significantly associated with the depth of tumor invasion (p = 0.042). In contrast, p53 was positive in 50.3% of the cases, and was associated with both age (p = 0.025) and the depth of tumor invasion (p = 0.014). There was no correlation between COX-2 expression and p53 expression (p = 0.118).ConclusionThese results suggest that COX-2 expression might play an important role in the progression of colorectal cancer. However, COX-2 expression was not associated with mutational p53. Further studies are needed to clarify the regulatory mechanisms governing COX-2 overexpression in colorectal cancers.
“…In agreement with other studies, p53 overexpression was found in 50.3% (81/161) of the colorectal cancers. Many other studies have demonstrated that p53 overexpression in colorectal cancer was closely related to clinicopathologic parameters and prognosis 12,19. In our study, p53 overexpression was correlated with age and depth of tumor invasion.…”
Section: Discussionsupporting
confidence: 75%
“…In our study, the expression rate of COX-2 was found to be 47.8% by immunohistochemical analysis, a result slightly lower than that found in other studies. However, other studies have reported that overexpression of COX-2 protein has been found in 21% to 25% of colorectal cancers 12-14. The discrepancies in the positive rate of COX-2 protein expression among the different studies may be explained by several factors, including variability in population size and characteristics, antibodies, lack of standardization in testing methods, and especially the differences in the choice of the scoring system or cutoff levels.…”
PurposeCyclooxygenase (COX)-2 is an inducible isoform responsive to cytokines, mitogens, and growth factors, and is believed to be an important enzyme related to colorectal cancer (CRC). Existing evidence suggests that COX-2 expression is normally suppressed by wild-type p53 but not mutant p53, suggesting that loss of p53 function may result in the induction of COX-2 expression. The aim of this study was to determine the relationship between COX-2 expression and p53 levels in CRC.Materials and MethodsPatients with sporadic colorectal adenocarcinoma (n = 161) who underwent curative surgery in Chosun University Hospital were enrolled in this study. Expression of COX-2 and p53 proteins was examined by immunohistochemistry in paraffin-embedded cancer tissue blocks, and the relationship between COX-2 and/or p53 expression with clinicopathologic parameters was analyzed.ResultsExpression of COX-2 was positive in 47.8% of colorectal cancers, and significantly associated with the depth of tumor invasion (p = 0.042). In contrast, p53 was positive in 50.3% of the cases, and was associated with both age (p = 0.025) and the depth of tumor invasion (p = 0.014). There was no correlation between COX-2 expression and p53 expression (p = 0.118).ConclusionThese results suggest that COX-2 expression might play an important role in the progression of colorectal cancer. However, COX-2 expression was not associated with mutational p53. Further studies are needed to clarify the regulatory mechanisms governing COX-2 overexpression in colorectal cancers.
“…Elevated COX-2 expression has been associated with poor prognoses in lung [40–42] and other cancers, such breast [43], head and neck [44], colon [45], and cervix carcinomas [46]. However, little is known about COX-2 single nucleotide polymorphisms in NSCLC.…”
Background. To further improve the screening, diagnosis, and therapy of patients with nonsmall cell lung cancer (NSCLC) additional diagnostic tools are urgently needed. Gene expression of Cyclooxygenase-2 (COX-2) has been linked to prognosis in patients with NSCLC. The role of the COX-2 926G>C Single Nucleotide Polymorphism (SNP) in patients with NSCLC remains unclear. The aim of this study was to investigate the potential of the COX-2 926G>C SNP as a molecular marker in this disease.
Methods. COX-2 926G>C SNP was analyzed in surgically resected tumor tissue of 85 patients with NSCLC using a PCR-based RFLP technique. Results. The COX-2 926G>C SNP genotypes were detected with the following frequencies: GG n = 62 (73%), GC n = 20 (23%), CC n = 3 (4%). There were no associations between COX-2 SNP genotype and histology, grading or gender detectable. COX-2 SNP was significantly associated with tumor stage (P = .032) and lymph node status (P = .016, Chi-square test). With a median followup of 85.9 months, the median survival was 59.7 months. There were no associations seen between the COX-2 SNP genotype and patients prognosis.
Conclusions. The COX-2 926G>C SNP is detectable at a high frequency in patients with NSCLC. The COX-2 926G>C SNP genotype is not a prognostic molecular marker in this disease. However, patients with the GC or CC genotype seem more susceptible to lymph node metastases and higher tumor stage than patients with the GG genotype. The results suggest COX-2 926G>C SNP as a molecular marker for lymph node involvement in this disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
